Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPD 161570 is a selective FGFR inhibitor (IC50 values are 40, 262 and 3700 nM for FGFR, PDGFR and EGFR respectively). Inhibits FGFR receptor phosphorylation (IC50 = 622 nM) and growth of A121 cells in vitro.
Sold for research purposes under agreement from Pfizer Inc.
PD 161570 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.
M. Wt | 532.51 |
Formula | C26H35Cl2N7O |
Storage | Store at -20°C |
Purity | ≥97% (HPLC) |
CAS Number | 192705-80-9 |
PubChem ID | 5328135 |
InChI Key | MKVMEJKNLUWFSQ-UHFFFAOYSA-N |
Smiles | ClC1=CC=CC(Cl)=C1C3=CC2=CN=C(NCCCCN(CC)CC)N=C2N=C3NC(NC(C)(C)C)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 53.25 | 100 | |
ethanol | 53.25 | 100 |
The following data is based on the product molecular weight 532.51. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.88 mL | 9.39 mL | 18.78 mL |
5 mM | 0.38 mL | 1.88 mL | 3.76 mL |
10 mM | 0.19 mL | 0.94 mL | 1.88 mL |
50 mM | 0.04 mL | 0.19 mL | 0.38 mL |
References are publications that support the biological activity of the product.
Hamby et al (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J.Med.Chem. 40 2296 PMID: 9240345
Batley et al (1998) Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 62 143 PMID: 9488112
Stevens et al (2003) Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol.Endocrinology 17 1751 PMID: 12805413
If you know of a relevant reference for PD 161570, please let us know.
Keywords: PD 161570, PD 161570 supplier, PD161570, selective, FGFR, inhibitors, inhibits, fibroblast, growth, factors, Pfizer, 3724, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for PD 161570 include:
Magaña et al (2014) Paracrine effects of embryo-derived FGF4 and BMP4 during pig trophoblast elongation. Dev Biol 387 15 PMID: 24445281
Rodríguez et al (2012) Modulation of pluripotency in the porcine embryo and iPS cells. J Exp Bot 7 e49079 PMID: 23145076
Tomohiro et al (2020) Regulation of NF-kB Signalling Through the PR55β-RelA Interaction in Osteoblasts. In Vivo 34 601-608 PMID: 32111759
Do you know of a great paper that uses PD 161570 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review PD 161570 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.